Two-year functional and anatomical results after converting treatment resistant eyes with exudative age-related macular degeneration to aflibercept in accordance with a treat and extend protocol-Reference-Cited by-同舟云学术

Two-year functional and anatomical results after converting treatment resistant eyes with exudative age-related macular degeneration to aflibercept in accordance with a treat and extend protocol

Published:2017-05-29 Issue:5 Volume:95 Page:460-463
ISSN:1755-375X
Container-title:Acta Ophthalmologica
language:en
Short-container-title:Acta Ophthalmol

Author:

Jørstad Øystein Kalsnes¹,Faber Rowan Thomas¹,Moe Morten Carstens¹

Affiliation:

1. Department of Ophthalmology; Oslo University Hospital and University of Oslo; Oslo Norway

Publisher

Wiley

Subject

Ophthalmology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/aos.13480/fullpdf

Reference13 articles.

1. The role of sub-retinal fluid in determining treatment outcomes in patients with neovascular age-related macular degeneration-a phase IV randomised clinical trial with ranibizumab: the FLUID study;Arnold;BMC Ophthalmol,2016

2. Visual acuity as an outcome measure in clinical trials of retinal diseases;Beck;Ophthalmology,2007

3. Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol;Berg;Ophthalmology,2015

4. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study;Brown;Ophthalmology,2009

5. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial;Chakravarthy;Lancet,2013

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Visual and anatomical outcomes associated with treat-and-extend administration of intravitreal aflibercept for neovascular age-related macular degeneration;International Journal of Retina and Vitreous;2021-09-27

2. Anti-VEGF-Resistant Retinal Diseases: A Review of the Latest Treatment Options;Cells;2021-04-29

3. Switching to aflibercept versus continuing bevacizumab for treatment‐resistant neovascular age‐related macular degeneration: a one‐year comparative observational study;Acta Ophthalmologica;2021-02-26

4. Disease stability and extended dosing under anti-VEGF treatment of exudative age-related macular degeneration (AMD) — a meta-analysis;Graefe's Archive for Clinical and Experimental Ophthalmology;2021-02-02

5. Switch to aflibercept in the treatment of neovascular age-related macular degeneration: 30-month results;Arquivos Brasileiros de Oftalmologia;2021